$IBRX News

ImmunityBio Achieves World's Broadest Bladder Cancer Approval as UAE Green Lights Lead Drug

Reported Earlier, ImmunityBio's ANKTIVA Wins UAE Nod For NSCLC After QUILT-3.055 Trial Showed 14.6-Month Median Overall Survival In Checkpoint-Refractory Patients

ImmunityBio: ANKTIVA's Commercial Momentum Supports A Buy

ImmunityBio: Intriguing Progress, If Not (Yet) Commercially - Still A Hold

ImmunityBio: A Long-Term Bull Case Worth Watching

ImmunityBio (NASDAQ:IBRX) Screens as a High-Growth Momentum Stock Passing Minervini’s Trend Template

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

ImmunityBio Presents Data At American Society Of Clinical Oncology Annual Meeting About Its Phase 3 Studies In Advanced Non-Small Cell Lung Cancer

ImmunityBio Announces Preliminary Results From News Economic Analysis Showing That Anktiva Plus Bacillus Calmette–Guérin Achieved A Lower Cost Per Sustained Complete Responder

ImmunityBio Announces New Survey Data Showing Diverse Treatment Preferences And Priorities Of Patients With Bacillus Calmette–Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer

BTIG Reiterates Buy on ImmunityBio, Maintains $12 Price Target

ImmunityBio: Could Be One Approval Away From A Multi-Billion Dollar Breakout

HC Wainwright & Co. Reiterates Buy on ImmunityBio, Maintains $15 Price Target

Reported Earlier, ImmunityBio Says FDA Accepted ANKTIVA Plus Bacillus Calmette-Guerin Filing For Papillary Non-Muscle Invasive Bladder Cancer Following Workshop Support And National Comprehensive Cancer Network Guidance

ImmunityBio: Looking Beyond Bladder Cancer To A Multibillion-Dollar Solid Tumor TAM

ImmunityBio Announces Results From Two ITC Analyses Presented At 2026 AUA Annual Meeting Evaluating Nogapendekin Alfa inbakicept-pmln Plus BCG

ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership

ImmunityBio Secures Five US Patents Covering Combination Of IL-15 Receptor Agonist ANKTIVA With Bacillus Calmette-Guérin For Treatment Of Cancer

Reported Saturday, ImmunityBio Secures Exclusive US Rights To Tokyo-172 BCG After Phase 3 Trial Shows Non-Inferior Efficacy To TICE BCG

ImmunityBio Stock Drops After Earnings Miss Despite Anktiva Momentum